- Home
- UWMC vs ADPT Comparison
UWMC vs ADPT Comparison
Compare UWMC & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UWMC
- ADPT
- Stock Information
- Founded
- UWMC 1986
- ADPT 2009
- Country
- UWMC United States
- ADPT United States
- Employees
- UWMC N/A
- ADPT N/A
- Industry
- UWMC Finance: Consumer Services
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- UWMC Finance
- ADPT Health Care
- Exchange
- UWMC Nasdaq
- ADPT Nasdaq
- Market Cap
- UWMC 940.0M
- ADPT 1.1B
- IPO Year
- UWMC N/A
- ADPT 2019
- Fundamental
- Price
- UWMC $4.24
- ADPT $9.03
- Analyst Decision
- UWMC Hold
- ADPT Buy
- Analyst Count
- UWMC 9
- ADPT 6
- Target Price
- UWMC $6.88
- ADPT $9.83
- AVG Volume (30 Days)
- UWMC 4.0M
- ADPT 3.0M
- Earning Date
- UWMC 05-06-2025
- ADPT 05-01-2025
- Dividend Yield
- UWMC 9.46%
- ADPT N/A
- EPS Growth
- UWMC N/A
- ADPT N/A
- EPS
- UWMC N/A
- ADPT N/A
- Revenue
- UWMC $2,486,541,000.00
- ADPT $189,527,000.00
- Revenue This Year
- UWMC $15.22
- ADPT $21.20
- Revenue Next Year
- UWMC $21.25
- ADPT $21.99
- P/E Ratio
- UWMC N/A
- ADPT N/A
- Revenue Growth
- UWMC 10.39
- ADPT 8.61
- 52 Week Low
- UWMC $4.04
- ADPT $2.99
- 52 Week High
- UWMC $9.74
- ADPT $10.28
- Technical
- Relative Strength Index (RSI)
- UWMC 37.31
- ADPT 57.82
- Support Level
- UWMC $4.04
- ADPT $8.38
- Resistance Level
- UWMC $4.91
- ADPT $9.51
- Average True Range (ATR)
- UWMC 0.22
- ADPT 0.66
- MACD
- UWMC 0.00
- ADPT 0.16
- Stochastic Oscillator
- UWMC 23.56
- ADPT 63.02
About UWMC UWM Holdings Corporation
UWM Holdings Corp engages in the origination, sale, and servicing of residential mortgage loans in the wholesale channel. The company provides independent mortgage advisors across the states and the district of Columbia.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).